Silencing of HIF-1α enhances the radiation sensitivity of human glioma growth in vitro and in vivo

被引:22
作者
Luo, Zhonghua [1 ]
Bai, Minghua [2 ]
Xiao, Xian [3 ]
Zhang, Wei [3 ]
Liu, Xuedong [4 ]
Yang, Xiaoliang [5 ]
Li, Sanzhong [3 ]
Huan, Yi [1 ]
Wu, Zhiqun [1 ]
Zhang, Xiang [3 ]
Cao, Weidong [3 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp, Dept Radiol, Xian 710032, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Oncol, Xian, Peoples R China
[3] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Shaanxi, Peoples R China
[4] Fourth Mil Med Univ, Xijing Hosp, Dept Neurol, Xian 710032, Shaanxi, Peoples R China
[5] 3rd Hosp People Liberat Army, Dept Neurosurg, Baoji, Peoples R China
基金
中国国家自然科学基金;
关键词
Gliomas; Radiation sensitivity; HIF-1; alpha; RNAi; Pathway; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; SQUAMOUS-CELL CARCINOMA; CANCER-CELLS; CHEMOTHERAPEUTIC DRUGS; INDUCED APOPTOSIS; MALIGNANT GLIOMA; UP-REGULATION; GLIOBLASTOMA; EXPRESSION; THERAPY;
D O I
10.1016/j.neuropharm.2014.05.009
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Gliomas are the leading cause of cancer-related mortality worldwide, and the incidence is increasing. Because gliomas often become resistant to radiation treatment, it is urgent to develop novel therapeutic methods that are more effective and less toxic than current therapies so as to enhance patient survival and quality of life. Effective enhancement of radiation therapy for gliomas in vivo and in vitro was observed upon silencing of hypoxia-inducible factor 1 alpha (HIF-1 alpha) with RNA interference; this enhancement was related to changes in the cell cycle and apoptosis that were accompanied by modulation of Cdc2, cyclin B1, and Bcl-2 expression. Our data suggest that HIF-1 alpha silencing combined with radiation therapy will increase the.therapeutic efficacy of glioma treatment via regulation of cell cycle and apoptosis-related signaling pathways. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:168 / 174
页数:7
相关论文
共 37 条
  • [1] Cao W.D., 2013, BRAIN TUMOR PATHOL, V1, DOI DOI 10.1007
  • [2] ELR510444 Inhibits Tumor Growth and Angiogenesis by Abrogating HIF Activity and Disrupting Microtubules in Renal Cell Carcinoma
    Carew, Jennifer S.
    Esquivel, Juan A., II
    Espitia, Claudia M.
    Schultes, Christoph M.
    Muelbaier, Marcel
    Lewis, Joe D.
    Janssen, Bernd
    Giles, Francis J.
    Nawrocki, Steffan T.
    [J]. PLOS ONE, 2012, 7 (01):
  • [3] RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression
    Cho, Hee Jun
    Baek, Kyoung Eun
    Park, Sun-Mi
    Kim, In-Kyu
    Nam, In-Koo
    Choi, Yeong-Lim
    Park, Seung-Ho
    Im, Min-Ju
    Choi, Jungil
    Ryu, Jinhyun
    Kim, Jae Won
    Lee, Chang Won
    Kang, Sang Soo
    Yoo, Jiyun
    [J]. CANCER LETTERS, 2011, 311 (01) : 48 - 56
  • [4] Cidon Esther Una, 2013, Cancers (Basel), V5, P64, DOI 10.3390/cancers5010064
  • [5] HIF-1α depletion results in SP1-mediated cell cycle disruption and alters the cellular response to chemotherapeutic drugs
    Culver, Carolyn
    Melvin, Andrew
    Mudie, Sharon
    Rocha, Sonia
    [J]. CELL CYCLE, 2011, 10 (08) : 1249 - 1260
  • [6] Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity
    Dash, BC
    El-Deiry, WS
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (08) : 3364 - 3387
  • [7] Drain N., 2011, ONCOGENE, V20, P260
  • [8] Overexpression of carbonic anhydrase and HIF-1α in Wilms tumours
    Dungwa, Josiah V.
    Hunt, Linda P.
    Ramani, Pramila
    [J]. BMC CANCER, 2011, 11
  • [9] Expression and Clinical Role of Antiapoptotic Proteins of the Bag, Heat Shock, and Bcl-2 Families in Effusions, Primary Tumors, and Solid Metastases in Ovarian Carcinoma
    Elstrand, Mari Bunkholt
    Kleinberg, Lilach
    Kohn, Elise C.
    Trope, Claes G.
    Davidson, Ben
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2009, 28 (03) : 211 - 221
  • [10] Optimal Management of Metastatic Renal Cell Carcinoma: Current Status
    Escudier, Bernard
    Albiges, Laurence
    Sonpavde, Guru
    [J]. DRUGS, 2013, 73 (05) : 427 - 438